AUTHOR INDEX

(BR) = Book reviewer; (C) = commentary; (E) = editorial; (L) = letter to the editor; (S) = supplement.

Abrams, D.B., 862
Ackerman, D., 989
Adan, A., 1599
Ahluwalia, N., 1065 (L)
Al-Adwani, A., 259
Alam, F., 165
Aleixandre, R., 387 (L)
Allebeck, P., 229
Allwright, S., 1279
Alterman, A.I., 411 (C)
Altmann, D.R., 749
Amill, A., 1147
Ammon, L.N., 1015
Amos, A., 77
Ana, M., 811
Andersen, A., 1489 (E)
Anderson, P., 295 (C), 299, 1367 (E), 1376 (C)
Angeles, M., 811
Anglin, M.D., 708
Anthony, J.C., 897, 1062 (L)
Arasteh, K., 885
Areán, P.A., 1286
Ariño, J., 103
Atakan, Z., 513 (L)
Aubin, H.J., 1206
Austin, M., 349

Babor, T.F., 1 (E), 1091 (C), 1235 (E)
Backmund, M., 1167
Badger, G.J., 855
Baker, A., 875
Bakoula, C., 1333
Baldwin, S., 1157
Ball, J.C., 393 (E)
Ball, S.A., 1610 (L)
Ballesteros, J., 103
Balmford, J., 369
Bangdiwala, S.I., 1147
Bareta, J., 946
Barker, B., 187
Barman, S.K., 1049
Barnard, M., 552
Barnett, P.G., 718
Bartley, M., 770
Bartu, A., 53
Basu, D., 785 (L)
Basu, N., 259 (L)
Batra, A., 1504 (C)
Baud, F.J., 978
Bedford, D., 1279
Berlin, I., 1206
Bernstein, E., 590
Bernstein, J., 590
Berrebi, A., 209
Berridge, V., 1375 (C)
Bickel, W.K., 855
Bidaut-Mazel, C., 1206
Bigelow, G.E., 1439
Bischof, G., 654 (BR)
Blacker, D.L, 1403
Bloor, R., 165
Bluthenthal, R.N., 1136
Bochner, F., 940
Bolier, L., 425
Bolliger, C.T., 634
Bond, J., 1111
Bonomo, Y.A., 1520
Borland, R., 369, 529 (E), 1042
Borrelli, B., 378
Borron, S.W., 978
Bossi, C., 1560
Bostock, Y., 77
Bowden-Jones, O., 1306
Bowes, G., 1520
Braine, N., 1081 (E)
Brandon, T.H., 51 (S1)
Brennan, P., 829
Britton, A., 109
Broekman, T.G., 416 (C)
Brogly, S.B., 727
Broome, K.M., 579
Brown, R.A., 862
Brown, S.A., 38 (S2)
Bruneau, J., 727
Bryant, W.K., 846
Bühringer, G., 1379 (C)
Bukstein, O.G., 23 (S2)
Burdette, S., 649 (L)
Burke, R.S., 1323
Busch, S., 93
Butler, S.F., 413 (C)

Çorapçıoğlu, A., 67
Cacciola, J.S., 411 (C)
Caetano, R., 1075 (E), 1608 (L), 1612
Caplehorn, J., 509 (L)
Carlin, J.B., 1520
Carmen, B., 811
Carr, M., 165
Carr, V.J., 875
Carroll, K.M., 349
Casey, T., 340
Cashell-Smith, M.L., 1410
Casswell, S., 738, 1378 (C)
Castellano, M., 387 (L)
Catalano, P., 1024
Chaloupka, F., 914
Chandola, T., 770
Chatkin, J.M., 778
Chaumerliac, C., 209
Chausmer, A.L., 1439
Cheinquer, H., 973
Chemali-Hudry, J., 1206
Chen, C.-Y., 897
Chen, H., 1176
Chick, J., 25 (C)
Chikritzhs, T., 1024
Civitelli, P., 1560
Claire, M., 875
Clark, D.B., 5 (S2)
Clark, S., 1121
Clayton, R.R., 1 (S1), 78 (S1)
Cochran, S.D., 989
Codde, J.P., 53
Coffey, C., 1520
Cohen, P.J., 259 (L)
Colby, S.M., 47 (S2), 862
Collin, J., 394 (E)
Conklin, C.A., 1 (S1), 78 (S1)
Constable, P., 875
Cook, C.C.H., 539, 1069 (BR)
Cooper, S., 1306
Cooper-Stanbury, M., 1024
Costa, P.T., Jr, 472
Courtwright, D.T., 1069 (BR)
Crome, I., 165
Cuijpers, P., 425, 839
Curran, H.V., 1450
Currie, S.R., 1121
Curry, S.J., 237
Czermak, C., 251

D'Arcy, C., 53
Damase-Michel, C., 209
Darke, S., 175, 275 (E), 1315
Davies, G., 1181
Davis, M., 621
de Abreu, C.M., 778
de Micheli, D., 570
DeFuentes-Merillas, L., 117
Degenhardt, L., 187
Del Boca, F.K., 1609 (L)
Delespaul, P., 1333
Delucchi, K.L., 718
Demers, A., 161
Dennis, M.L., 120 (S2), 129 (S2)
Des Jarlais, D.C., 885, 1081 (E), 1355 (L)
Diacon, A.H., 634
Dickerson, M., 1479 (BR)
Dickow, A., 708
Digiusto, E., 450
Donath, S., 1024, 1157
Donghua, M., 1355 (L)
Donmall, M.C., 955
Dormitzer, C.M., 897
Dorn, J., 313
Doshi, R., 1542
Downey, J., 1279
Dresler, C.M., 83
Drummond, D.C., 1542
Duchovny, N., 93
Dunn, J., 1133
Dunn, R., 999

Edwards, B.Q., 262 (L), 1503 (C)
Edwards, G., 7 (E), 149, 159, 929 (BR), 1067 (BR), 1235 (E), 1360 (BR)
Ehrenreich, H., 26 (C)
Eissenberg, T., 5 (S1)
el-Guebaly, N., 1121
Emelyanova, Z., 1565

© 2004 Society for the Study of Addiction

Epstein, J., 938 (E)
Esposito-Smythers, C., 47 (S2)
Etter J.-F., 1342

Falba, T., 93
Falkner, K., 313
Fan, C., 1176
Fang, Y., 1103
Farringdon, F., 278
Fearer, S.A., 1323
Fendrich, M., 197
Fergusson, D.M., 512 (L), 651 (L), 1147, 1351 (L), 1480 (BR), 1529
Fillmore, M.T., 1237, 1252 (C)
Finn, P.R., 1248 (C)
Fischer, B., 663 (E)
Fitzmaurice, G., 1403
Flaherty, B.P., 262 (L)
Flay, B.R., 914
Fong, G.T., 1042
Fonseca, A., 973
Formigoni, M.L.O.S., 570
Foster, J., 654 (BR)
Foxcroft, D., 133 (BR)
Franco, E.L., 727
Frank, G., 1298
Frazier, Y., 708
Freeman, N.C., 53
French, D.J., 482
Freudenheim, J.L., 313
Friedman, S.R., 885
Friedmann, P.D., 962
Fritscher, C.C., 778
Fry, C.L., 1157
Fuller, R.K., 21, 27 (C)
Funk, R., 120 (S2)
Funk, R.R., 129 (S2)
Furst, R.T., 431

Gable, R.S., 686
Galai, N., 946
Galea, J., 431
Galea, S., 846
Gallagher, C., 708
Gallagher, S.J., 1410
Galloway, G.P., 708
Galperim, B., 973
Garretsen, H., 161
Gastpar, M., 267 (BR)
Gawthorne, G.S., 53
Gerstein, D.R., 516 (BR), 962
Gfroerer, J., 938 (E)
Gil, A.G., 106 (S2), 140 (S2)
Gilmore, A., 1577
Gilmore, A.B., 394 (E)
Gilmore, I.T., 1487 (E)
Giordano, L.A., 855
Giovino, G., 914
Giudicelli, C.P., 978
Glautier, S., 30 (S1)
Gmel, G., 154, 331
Gómez, M., 1147
Godfrey, C., 697
Godley, M.D., 120 (S2), 129 (S2)
Godley, S.H., 120 (S2), 129 (S2)
González, G.B., 897
González-Pinto, A., 103
Gordis, E., 21, 27 (C), 152
Gordon, A., 862
Gossop, M., 697
Grønbæk, M., 323
Graham, K., 663 (E), 1250 (C)
Grant, S., 1504 (C)
Grant, T., 875
Grau, L.E., 1136
Greenfield, T.K., 145 (E), 415 (C), 1111
Grotto, I., 641
Grover, S., 785 (L)
Gruenewald, P.J., 1249 (C)
Gruenwald, P.J., 598
Gual, A., 1376 (C)
Gulliver, S.B., 862
Gutiérrez, U., 897
Gwaltney, C.J., 51 (S1)

Haas, A.L., 5 (E)
Haber, P., 135 (BR)
Haerpfer, C.W., 1577
Haggsträm, F.M., 778
Hall, S.M., 718
Hall, W., 153, 511 (L), 560, 1064 (L), 1235 (E), 1481 (BR)
Hamilton, G., 293 (C)
Hammett, T.M., 1355 (L)
Hammond, D., 1042
Hao, W., 1176
Hauge, R., 1094
Haw, S., 77
Haydon, E., 663 (E)
Head, J., 770
Heeren, T., 590
Heimer, R., 1136
Heinz, A., 1167, 1482 (BR)
Hendrickson, J.C., 962
Henquet, C., 1333
Henry, J.A., 1233 (E)
Herrell, J., 708
Herrmann, C., 431
Herzog, T.A., 51 (S1)
Hickman, M., 650 (L), 1430
Higuchi, S., 419
Hill, L., 292 (C)
Hingson, R., 590
Hitsman, B., 378
Hjern, A., 229
Höfler, M., 1586
Ho, S.Y., 1195
Hoch, E., 1586
Hodgins, D.C., 1121
Hodgson, R., 3 (E)
Holder, H.D., 517 (BR)
Holman, J., 53
Homel, R., 1251 (C)
Hope, V., 1430
Horton, N.J., 361
Horwood, L.J., 651 (L), 1529
Hovey, K., 313
Howell, E., 131 (L)
Howell, F., 1279
Hubbell, A., 197
Huber, A., 708
Hudson, J.I., 1189
Hughes, J.R., 29
Humfleet, G.L., 5 (E)
Humphreys, K., 155, 1221
Hunt, D., 369
Hunt, K., 431
Hunter, R.F., 1147

Iacono, W.G., 1548
Ikuta, N., 973
Ionescu-Pioggia, M., 1189
Iqbal, M.Z., 1306
Irvin, J.E., 51 (S1)

Jack, L.M., 237
Jaffe, J.H., 165
James, D., 1181
Jané-Llopis, E., 299
Javitz, H.S., 237
Jenner, L., 875
Jensen, M.K., 323
Jofre-Bonet, M., 93
John, B., 3 (E)
Johnson, T., 197
Johnston, L.D., 914
Judd, A., 621, 1306

Kalant, H., 653 (BR)
Kaminer, Y., 93 (S2)
Kanayama, G., 1189
Kaprio, J., 1049
Karavashkin, V., 1430
Kark, J.D., 641
Kaskutas, L.A., 1015, 1393
Kaye, S., 1315
Kay-Lambkin, F., 875
Keely, J., 29
Keenan, E., 1064 (L)
Kelly, E., 175
Kerr, W.C., 1111, 1231 (E)
Ketterman, R.L., 482
Khutorksoy, M., 1430
King, S.M., 1548
Kirby, K.N. 461
Kleber, H.D., 1476 (L)
Klingemann, H., 787 (BR), 1418
Kloska, D.D., 914
Koeter, M.W.J., 117, 416 (C)
Kozlowski, L.T., 262 (L), 1503 (C)
Krampe, H., 26 (C)
Küfner, H., 1360 (BR)
Kumaranayake, L., 1565
Kuntsche, E.N., 331
Kypri, K., 1410

Lacroix, I., 209
Lagrue, G., 1206
Lai, M.K., 1195
Lam, T.H., 1195
Lamothe, F., 727
Lang, A.R., 482

© 2004 Society for the Study of Addiction

Langley, J.D., 1410
Lapeyre-Mestre, M., 209
Lapham, S.C., 598, 607, 612
Laranjeira, R., 1133
Layne, L., 598
Lebargy, F., 1206
Lee, C.S., 47 (S2)
Lee, K., 394 (E)
Lee, N.K., 875
Lehofer, M., 251
Leigh, B.C. 215
Lemmers, L., 839
Lemonis, L., 251
Leung, R., 431
Levenson, S., 590
Lewin, T.J., 875
Lewis, G., 1353 (L)
Lewis-Esquerre, J., 47 (S2)
Liddle, H.A., 76 (S2)
Lieb, R., 1586
Liebmann, P.M., 251
Liebson, I.A., 1439
Lintzeris, N., 1157
Liu, I.-C., 1403
Liu, T., 1176
Loree, M., 260 (L)
Lowman, C., 1 (S2)
Lu, Y., 1103
Lubman, D.I., 1491, 1506 (C)
Lugoboni, F., 1560
Lunge, V., 973
Lyons, M.J., 1403

Mäkelä, K., 398, 417 (C), 923 (L)
Macleod, J., 650 (L)
Maher, L., 929 (BR)
Malik, M.R., 1136
Mann, K., 1361 (BR)
Mann, R.E., 663 (E)
Mansfield, D., 786 (BR)
María, A.J., 811
Marinelli-Casey, P., 708
Marlatt, A., 789 (BR)
Marmot, M., 109, 1090 (C)
Marsden, J., 1235 (E)
Marshall, P., 1136
Martin, R.A., 862
Maruyama, K., 419 (C)
Masson, C.L., 718
Mateo, C., 1024
Mattick, R.P., 450
Maynard, A., 129 (L)
Mays, V.M., 989
McAfee, T., 237
McAuliffe, W.E., 999, 1219 (L)
McBride, N., 278, 296 (C)
McCambridge, J., 39, 157, 388 (L), 1477 (L)
McCann, M.J., 708
McClure, R.J., 1262
Mccrady, B.S., 152
McDonald, P.W., 1042
McElduff, P., 955
McEvoy, P.M., 482
McEwen, A., 1470
McFadden, M., 340
McGee, R.O., 1410
McGue, M., 1548
McKee, M., 1577
Mckeganey, N., 265 (BR), 552
McMillan, G.P., 612
McNeill, A., 77
McPherson, K., 661 (E)
McPherson, M., 738
Mehta, S.H., 946
Meier, P.S., 955
Meli, S., 361
Mertens, J.R., 1286
Mesquita, F., 799 (E)
Meuleners, L., 278
Meyer, R.E., 165
Mezzelani, P., 1560
Midanik, L.T., 145 (E), 1479 (BR)
Midford, R., 278
Mikhailova, L., 1430
Mitchell, T.B., 940
Monaghan, L., 1450
Montastruc, J.L., 209
Monti, P.M., 47 (S2), 63 (S2), 862
Moos, B.S., 829
Moos, R.H., 829, 923 (L)
Morgan C.J.A., 1450
Moskalewicz, J., 1377 (C)
Muehlig, S., 1586
Mueller, T.I., 862
Munro, G., 1370, 1380 (C)
Munro, G.D., 498
Muti, P., 313
Mwesigye, S.-E., 340
Myers, M.G., 862

Nanchahal, K., 749
Naud, S., 29
Nayak, M.B., 1393
Neale, J., 156
Nelson, K.E., 946
Nemtsov, A., 386 (L)
Neumark, Y.D., 641
Ngu, D., 1355 (L)
Niaura, R., 378
Nich, C., 349
Nochajaski, T., 313
Norström, T., 1274
Numan, N., 61

Ögel, K., 67
O'Brien, S., 450
O'Connor, R.J., 262 (L)
O'Farrell, A., 1279
O'Leary Tevyaw, T., 63 (S2)
O'Malley, P.M., 914
O'Shea, J., 1064 (L)
Obert, J., 708
Oei, T.P.S., 757
Orford, J., 1356 (L)
Overvad, K., 323
Owen, L., 1470

Pajusco, B., 1560
Palepu, A., 361
Pantelis, C., 1491, 1506 (C)
Papandonatos, G., 378
Patton, G.C., 1520
Pérez, R.L., 1067 (BR)
Pennell, S., 708
Perlis, T.E., 885
Petry, N.M., 349, 461, 1475 (L)
Phillips, M., 278
Picciano, J.F., 1323
Pierce, J., 914
Piper, T.M., 846
Pirnay, S., 978
Platt, L., 1430
Pledger, M., 738
Pohlman, S., 875
Poikolainen, K., 26 (C), 276 (E), 1362 (BR)
Polsky, D., 130 (L)
Pomerleau, J., 1577
Pope, H.G., Jr. 1189
Prat, G., 1599
Pridemore, W.A., 1034, 1357 (L)
Prietl, B., 251
Pulkkinen, L., 1049
Purdie, D.M., 1262

Qiu, X., 1103
Quaglio, G., 1560
Querejeta, I., 103

Ram, M., 313
Ramstedt, M., 1255
Rao, S.R., 579
Rawson, R.A., 708
Raylu, N., 757
Rehm, J., 663 (E), 1111
Reiber, C., 708
Remer, L., 598
Renton, A., 1430
Rhodes, T., 621, 1430
Ríos, E., 1147
Ribeiro, M., 1133
Ricordel, I., 978
Riper, H., 839
Roche, A., 294 (C), 450, 510 (L), 1157
Roche, A.M., 1262
Rockstroh, B., 1482 (BR)
Roffman, R.A., 1323
Rohay, J.M., 83
Rohrhofer, A., 251
Rohsenow, D.J., 862
Roman, J., 131 (L)
Romanò, L., 1560
Romantzov, V., 1565
Room, R., 161, 655 (BR), 663 (E), 925, 928 (BR), 1083, 1092 (C)
Rose, R.J., 1049, 1577
Rosen, A., 718
Ross, J., 175
Ross, M.W., 989
Rossow, I., 161, 937 (E), 1094
Rounsaville, B.J., 266 (BR), 349

© 2004 Society for the Study of Addiction

Ruel, E., 914
Russell, M., 313
Rutter, M., 1359 (BR)

Sánchez-Turet, M., 1599
Samet, J.H., 361
Samoshkin, S., 1565
Sampuran, A.K., 1542
Sarkar, S., 799 (E)
Satre, D.D., 1286
Saunders, J.B., 875, 1410
Savva, S., 7 (E)
Schaefer, M., 1167
Scharf, D., 1462
Schauenstein, K., 251
Scheidt, D.M., 1508
Scherbaum, N., 520 (BR)
Schibli, D., 1418
Schippers, G.M., 117, 416 (C)
Schofield, P.E., 498
Schutte, K., 829
Schuurmans, M.M., 634
Sees, K.L., 718
Seivewright, N., 265 (BR), 1306
Sell, L., 442
Sesso, R., 1133
Shakeshaft, A., 450
Shiffman, S., 1 (S1), 78 (S1), 83, 1462
Sigmon, S.C., 1439
Simmons, A., 165
Simpson, D.D., 579
Sindelar, J., 93
Singer, M., 1136
Skipper, B.J., 607
Smart, R.G., 151
Smit, F., 425, 515 (L)
Smith, G.D., 650 (L)
Smithson, M., 340
Snow, P.C., 498
Somogyi, A.A., 940
Spiehler, V., 197
Spilimbergo, I., 1560
Spring, B., 378
Stacy, A.W., 215
Stefanis, C.N., 1333
Stefanis, N.C., 1333
Stein, A., 973
Stenius, K., 412 (C)
Stephens, R.S., 1323
Stewart, D., 697
Stockwell, T., 1024, 1090 (C)
Strang, J., 39
Strathdee, S.A., 946
Stritzke W.G.K., 482
Su, Z., 1176
Sundquist, K., 1298
Swan, G.E., 237

Tardiff, K.J., 846
Tassiopoulos, K., 590
Tedford, J., 349
Teesson, M., 1352 (L)
Terracciano, A., 472
Thom, B., 518 (BR)
Thomas Mclellan, A., 411 (C)
Thoumi, F.E., 135 (BR)
Tibbetts, N., 361
Tiffany, S.T., 1 (S1), 78 (S1)
Tilling, K., 1430
Tjønneland, A., 323
Tober, G., 677
Toce-Gerstein, M., 267 (BR)
Tolstrup, J.S., 323
Tomar, S.L., 260 (L)
Topp, L., 187
Toumbourou, J.W., 498
Tourneau, J., 978
Tracy, M., 846
Trevisan, M., 313
Tsuang, M.T., 1403
Tubman, J.G., 106 (S2), 140 (S2)
Tucker, T., 1157
Turner, C.F., 885
Tyndall, M.W., 727
Tyrer, P., 1306

Ugland, T., 161
Ussher, M., 1542

Valderrama Zurián, J.C., 387 (L)
van Biljon, X., 634
van den Brink, W., 117, 416 (C)
Van Os, J., 1333
Van, L.K., 1355 (L)
Vandersloot, D., 708
Verity, R., 649 (L)
Vickerman, P., 1565
Vittetoe, K., 897
Vlahov, D., 846, 946
Vlasov, A., 1430
Vogel-Sprott, M., 1247 (C)

Wagner, E.F., 106 (S2), 140 (S2)
Wagner, E.M., 251
Wagner, M.B., 778
Wakefield, M., 914
Waldron, H., 120 (S2)
Waldron, H.B., 93 (S2)
Walker, D., 1565
Wang, C.-L., 946
Wang, J., 1103
Warner, J., 788 (BR)
Watt, K., 1262
Watts, C., 1565
Weafer, J., 1237, 1252 (C)
Weaver, T., 1306
Wei, L., 1355 (L)
Weisner, C., 1286
Weiss, R.D., 1382
Wells, J.E., 1529
West, R., 1235 (E), 1470, 1542
Westermeyer, J., 802 (E)
Whelan, G., 1157
White, I.R., 749
White, J.M., 940
White, V.M., 498
White, W.L., 532
Williams, C., 1323
Williams, I.R., 498
Williams, S.M., 1410
Willner, P., 1181
Wiltshire, S., 77
Windle, M., 1508
Winters, K., 23 (S2)
Wislar, J.S., 197
Wittchen H.-U., 1586
Witton, J., 786 (BR)
Wodak, A., 519 (BR), 799 (E), 1063 (L)
Wong, C.J., 1439
Wong, W., 718
Wright, D., 938 (E)

Xiao, S., 1176
Xu, R., 1403

Ye, Y., 1111
Young, D., 1176
Yücel, M., 1491, 1506 (C)

Zador, D., 442
Zammit, S., 1353 (L)
Zemore, S.E., 1015
Zhang, J., 1103
Zhang, Z., 962
Zviagin, V., 1565
Zweben, J., 708

© 2004 Society for the Study of Addiction

SUBJECT INDEX

(BR) = book review; (C)/(Cs) = commentary/ies; (E) = editorial; (IC) = iguana column; (L)/(Ls) = letter/s; (N&N) = news & notes; (S1) & (S2) = supplements.

acamprosate and naltrexone in treatment of alcohol dependence 811
acute alcohol consumption, risk of injury and influence of confounders 1262
acute effect of brief bout of exercise on alcohol urges 1542
acute lethal toxicity of commonly abused psychoactive substances, comparison 686
Addiction
  Book Prize 2003 790
  citation count analysis (2001) 387(L)
  editorial re-organization, Regional Office of the Americas 1(E)
  Online Early 7(E)
addiction recovery mutual aid groups (photo history series) 532
Addiction Severity Index (ASI), reliability and validity studies 398, 411(C)
addictology, new coinage and new academic department, Czech Republic 1071(N&N)
adherence
  combined hepatitis A and B vaccine in illicit drug users 1560
  experimenter-designed quit dates for smoking cessation 378
  to highly active antiretroviral therapy 361, 1064(L)
  to pharmacotherapy in patients with alcohol and opioid dependency 1382
adolescence *see* alcohol *and specific drugs*
adverse events, serious, in Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD) 450
Afghanistan *see* Kabul report
age groups
  alcohol expectancies and drinking in different 215
  disaggregating consequences of alcohol by 661(E)
  five-year alcohol and drug treatment outcomes 1286
age–period–cohort models, US National Alcohol Surveys 1111
ageing *see* older people
AIDS
  changing profiles of injecting drug users, Hispanic population 1147
  see also HIV
alcohol
  acute consumption, risk of injury from, and influence of confounders 1262
acute effect of brief bout of exercise on urges 1542
adolescents
  drinking patterns in mid-adolescence 1529
  emotional wellbeing and violence 331
  onset of alcohol dependence: cohort study over seven years 1520
  prediction of harm from controlled drinking strategies 498
  research perspectives on treatment 1–140(S2)
age issues 111, 215, 661(E), 829, 1286
in Australia: new report 269(N&N)
in Brazil: recent public health aspects 524(N&N)
brief interventions 3(E), 63(S2), 103, 839, 934(N&N), 1121, 1410
in Chinese city: prevalence and risk factors 1103
craving, comparison of three models 482
drinking patterns 276(E), 313, 323, 749, 829, 1393, 1529
drive-up liquor window closure studies, New Mexico 598, 607
extent and distribution of social harms from others' drinking 1094
gender issues 3(E), 103, 323, 661(E), 738, 829, 1237, 1247(C), 1253
and heart disease 109, 276(E), 313
and homicide, Russia 937(E), 1034, 1356(L)
and hospital admissions 1279, 1298
and immigrants, first- and second-generation 229
impairment of behaviour in men and women 1237, 1247(C), 1253
injury fund, South African doctors call for 141(N&N)
life-course approach to heavy drinking research 1489(E)
moderate use and health-care costs, propensity analysis of female health-care workers 612
mortality 323, 749, 839, 1231(E), 1255, 1274, 1364(BR)
and older people 829, 1286
and pancreatitis 1231(E), 1255
and pregnancy 1069(BR), 1393
research awards 1071(N&N), 1226(N&N)
research as a career 152
in Russia 386(L), 937(E), 1034, 1356(L)
in Sweden 229, 1298
under-reporting of consumption in household surveys 1024
and violence 331, 937(E), 1034, 1356(L)
see also scientific societies
alcohol dependence
  adherence to pharmacotherapy in patients with 1382
  alcoholic subtypes 1508, 1608(Ls)
  efficacy and safety of naltrexone and acamprosate in treatment 811
  genetic and environmental contributions to age of onset, male twins 1403
  recovery mutual aid groups: enduring international phenomenon 532
  reduced dopamine D4 receptor mRNA expression in lymphocytes of long-term abstinent addicts 251
  role of disulfram in treatment 21, 25(C), 785(L)
  teenage drinking and onset of, cohort study over seven years 1520
alcohol industry
  addiction agency collaboration: *Moo Joose* case study 1370, 1375(C), 1380
  research funding 935(IC)
  to help decide public funding of research and professional training: decision should be reversed 1235(E)
  whisky distillery, Scotland 269(N&N)
Alcohol Information Scotland, online 792(N&N)
alcohol policy
  APIS, NIAAA, US 270(N&N)
  Drink and British Politics Since 1830. A Study in Policy-Making 518(BR)
  Effects of Nordic Alcohol Policies: What Happens to Drinking and Harm When Alcohol Controls Change? 517(BR)
  Global Report on Alcohol Policy (WHO) 1363(N&N)
  International Centre (ICAP) 658(IC)
  Introduction to Alcohol Research: Implications for Treatment, Prevention and Policy 1479(BR)
  Japanese sales deregulation 141(N&N)
  Liquor Control 925(BR)
  National Alcohol Harm Reduction Strategy for England 1487(E)
  state of world's 1367(E)
  UK 518(BR), 1083, 1090(C), 1477(L), 1487(E)

© 2004 Society for the Study of Addiction

alcohol publications
Alcohol and Poverty in Sri Lanka 1067(BR)
American Drinking Practices 1612(BR)
Booze: A Distilled History 928(BR)
Calling Time report 791(N&N)
Conceiving Risk, Bearing Responsibility: Fetal Alcohol Syndrome and the Diagnosis of Moral Disorder 1069(BR)
Drunkards Refuge: The Lessons of the New York State Inebriate Asylum 1360(BR)
Manhood Lost. Fallen Drunkards and Redeeming Women in the Nineteenth-Century 788(BR)
Spirits of America: a Social History of Alcohol 929(BR)
Treatment of Drinking Problems: a Guide for the Helping Professions 135(BR)
Wine: A Scientific Exploration 1362(BR)
see also alcohol policy
alcoholics/alcoholism *see* alcohol dependence
ambivalence
alcohol craving model 482
Marijuana Check-up 1323
amphetamine
craving, development and initial validation of questionnaire to measure 1181
dependence 708
mortality in cohort of opiate and, users 53
use patterns and mental health of regular users during reported 'heroin drought' 875
anabolic steroid users' attitudes toward physicians 1189
antisocial personality disorder, alcoholic subtype 1508
ATTAIN project (Alcohol Treatment Targeting Adolescents in Need) 140(S1)
Australia
amphetamine users 53, 875
cocaine users, non-fatal overdose 1315
drinking trends: new report 269(N&N)
drug driving among injecting drug users 175
ecstasy use patterns 187
heroin dependence, research and policy responses 560, 1063(Ls)
heroin shortage 340, 875, 1063(Ls)
mortality in opiate and amphetamine users 53
serious adverse events, opioid dependence (NEPOD) 450
Australian Professional Society on Alcohol and other Drugs Conference (APSAD) 525(N&N)

Bad Neighbor Policy: Washington's Futile War on Drugs in Latin America 135(BR)
behavioural autarcesis 897, 923(Ls), 1062(L)
Belarus 1364(BR), 1577
benzodiazepines 165, 978
Biology of Gambling 1479(BR)
Bouncers: Violence and Governance in the Night Time Economy 265(BR)
Brazil
abstinence rates and outcome predictors for smoking cessation 778
alcohol in: recent public health aspects 524(N&N)
crack cocaine users, high mortality 1133
drug use by students 570
brief bout of exercise, effect on alcohol urges 1542
brief interventions
alcohol use 3(E), 63(S2), 103, 839, 934(N&N), 1121, 1410
injectors, hepatitis C virus risk 1157
Marijuana Check-up 1323
see also single-session motivational interviewing
Britain *see* UK
buprenorphine
-associated and methadone-associated deaths 978
injection depot formula: placebo comparison 1439, 1475(Ls)
in pregnant opioid-dependent women: prospective study 209
serious adverse events, NEPOD 450
bupropion
and gender differences 237, 1462
GP prescribing, England and Wales 1470
predictors of successful outcome, France 1206

Canada
new appointment 791(N&N)
per capita alcohol consumption and all-cause mortality 1274
cannabis/marijuana 129(S2)
Cannabis. Report of the Senate Special Committee on Illegal Drugs 653(BR)
Cannabis Use and Dependence: Public Health and Public Policy 786(BR)
and educational achievement, preventing frequent use 650(Ls)
exposure and adolescent behavioural autarcesis 897, 923(Ls), 1062(L)
as 'gateway' drug to nicotine dependence 5(E), 77
Global Appraisal of Individual Needs (GAIN) and Timeline Followback (TLFB; Form 90) 120(S2)
Marijuana Check-up 1323
medicinal, Canadian pharmacies may stock 791
and psychosis/schizophrenia 425, 511(Ls), 1333, 1351(Ls), 1480(BR)
relapse among adolescents discharged from out-patient treatment 129(S2)
single-session motivational interviewing 39
cardiovascular disease *see* heart disease
career issues, addiction researchers 149(E), 151, 152, 159
childbearing age, drinking patterns in national sample of women 1393
childhood externalising and internalizing psychopathology in prediction of early substance abuse 1548
China
alcohol abuse in metropolitan city: prevalence and risk factors 1103
drug use in high-prevalence areas 1176
Narcotic Culture: A History of Drugs in China 1067(BR)
perceived peer smoking prevalence and its association with smoking behaviours and intentions 1195
cigarettes *see* nicotine dependence; smoking; smoking cessation
cocaine
discount rates for delayed rewards 461
intranasal use and HCV infection 973
mortality among crack users, Brazil 1133
motivational enhancement and coping skills training 862
non-fatal over-dose among injecting and non-injecting users 1315
prize reinforcement contingency management 349
seen through users' eyes 1233(E)
use by heroin users, hair testing and self-report 590
cognition
Gambling Related Cognitions Scale (GRCS) 757
motivational enhancement and coping skills training for cocaine abusers 862

© 2004 Society for the Study of Addiction

Cognitive models of drug dependence 51(S1), 80(S1)
cognitive and subjective effects of ketamine 1450
cognitive-behavioural treatment
for adolescent substance abuse 93(S2)
Cognitive-Behavioural Integrated Treatment (C-BIT): a Treatment Manual for Substance Misuse in People with Severe Mental Health Problems 789(BR)
for insomnia in recovering alcoholics 1121
for methamphetamine dependence 708
comorbidity
alcoholic subtypes 1508
drug use patterns and mental health during reported 'heroin drought' 875
personality disorder and associated, in alcohol and drug services 1306
treatment of chronic hepatitis C in patients with drug dependence 1167
see also dual diagnosis
compulsive behaviour, evidence of inhibitory disregulation 1491, 1503(C)
contingency management, treatment of cocaine users 349
coronary heart disease *see* heart disease
costs/cost-effectiveness *see* economic analyses
counselling for smoking cessation
and pharmacotherapy 778
telephone 907
crack cocaine users, Brazil, high mortality 1133
craving
alcohol, comparison of three models 482
amphetamine, development of questionnaire 1181
neuroimaging and neuropsychological evidence of inhibitory dysregulation 1491, 1503(C)
culturally sensitive substance abuse intervention for Hispanic and African American adolescents 140(S1)
Czech Republic, addictology 1071(N&N)

deaths *see* mortality
delay-discounting, heroin and cocaine abusers versus alcoholics controls 461
depression
and adolescent alcohol use 331, 1520
and hostility as predictors of long-term outcomes among opiate users 579
developing countries drug research
Kabul report 802(E)
direct telemarketing of interventions, smoking cessation 907
disulfiram 21, 25(C), 785(L)
diurnal variations of activation and mood in nicotine dependence 1599
dopamine D4 receptor mRNA expression in abstinent alcohol and heroin addicts 251
drinking *see* alcohol; alcohol dependence; alcohol policy; alcohol publications
driving
alcohol-involved crashes, effect of New Mexico's 1998 drive-up liquor window closure 598
injecting drug users in Sydney, Australia 175
Drug Misuse and Community Pharmacy 265(BR)
drug policy
Bad Neighbor Policy: Washington's Futile War on Drugs in Latin America 135(BR)
impact of user groups 525(N&N)
and the public good? 388(L)
drug production, Pakistan–Afghanistan Border 786(BR)
drug research, in developing countries, Kabul report 802(E)
drug testing, utility in epidemiological research 197
Drug Use Screening Inventory (DUSI) 570
drug use/users
in Amsterdam 389(N&N)
in Asia 389(N&N)
Brazilian students 570
in China, high-prevalence areas 1176
economic analysis, National Treatment Outcome Research (NTORS) 697
exposure and adolescent behavioural autarcesis 897, 923(Ls), 1062(L)
fall in rate among young, NIDA report 934(N&N)
and homosexuality, US 946, 989
needs–health service match 962
parental 552, 955
Shooting Stars: Drugs, Hollywood and the Movies 1069(BR)
Survival of the Coolest 787(BR)
treatment planning guide 525(N&N)
treatment programs, audio-computerized versus face-to-face interviewing 885
young Israelis completing military duty, twenty-year trends in 641
see also injecting drug use; *specific drugs and treatments*
drug workers, new resources 934(N&N)
drug-dependence research, comment on Hall *et al.* 2003 259(L)
dual diagnosis
Cognitive-Behavioural Integrated Treatment (C-BIT): a Treatment Manual for Substance Misuse in People with Severe Mental Health Problems 789(BR)
Dual Diagnosis. Key Readings in Addiction Psychiatry 654(BR)
Integrated Treatment for Mood and Substance Use Disorders 266(BR)
Integrating Treatment for Dual Disorders. A Guide to Effective Practice 654(BR)
see also comorbidity

economic analyses 129(Ls)
alcohol
drive-up liquor window closure, New Mexico 607
moderate use and health-care utilization 612
tax proposal, France 390(N&N)
drugs
heroin price disparity, New York State 431
HIV preventive measures among injectors, Belarus 1565
standard maintenance treatment versus enriched 180-day methadone detoxification 718
National Treatment Outcome Research (NTORS) 697
ecstasy
factors associated with use, Turkish students 67
patterns of use, Australia 187
emotional wellbeing and violence among risky 331
environment
and genetic contributions to age of onset of alcohol dependence 1403
importance in relationship between substance use and harm 663(E)
epidemiology
alcohol and coronary heart disease 313
buprenorphine in pregnancy 209
determinants of sustained injection cessation 727
drug testing, utility of 197
drug use by Brazilian students 570
drug use by young Israelis 641
drug use in high-prevalence areas, China 1176
ecstasy use, Turkish students 67
Kettil Bruun Society 161
ethnicity *see* culturally sensitive substance abuse intervention

© 2004 Society for the Study of Addiction

European Association of Libraries and Information Services on Alcohol and other Drugs (ELISAD) 657(N&N)
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
drug consumption rooms report 792(N&N)
drug information system 1484(N&N)
online summaries 1364(N&N)
evidence-based interventions for adolescent alcohol use disorders 1(S2)
evolutionary approach to drug dependence 855
excessive sweating, methadone and 259(L)
Exchange on Drug Demand Reduction Actions (EDDRA), online database 1072(N&N)
exercise and alcohol urges, acute effect of brief bout 1542

family
drug use by Brazilian students 570
see also entries beginning genetic *and* parental
family-based therapies for alcohol and drug use 76(S2)
Five-Factor Model (FFM) of personality, smoking and 472
five-year alcohol and drug treatment outcomes of older adults versus middle-aged and younger adults 1286
fluoxetine, smoking cessation 378
former Soviet Union
determinants of smoking in eight countries 1577
see also Russia

gambling
Biology of Gambling 1479(BR)
low income and vulnerability 1356(L)
scratchcard, temporal stability in adult buyers 117
Sociology of Gambling 267(BR)
Gambling and Problem Gambling in Great Britain 516(BR)
Gambling Related Cognitions Scale (GRCS): development 757
gender
alcohol consumption and drinking problems among older women and men 829
alcohol impairment behaviour in men and women 1237, 1247(C), 1253
brief alcohol interventions 3(E), 103
convergence in alcohol consumption and related problems, New Zealand 738
disaggregating consequences of alcohol by 661(E)
drinking patterns and mortality in middle-aged men and women 323
extent and distribution of social harms from others' drinking 1094
smoking cessation 237, 378, 1462
genetic and environmental contributions to age of onset of alcohol dependence 1403
German Society for Addiction Research and Therapy, 15th Scientific Congress 1072(N&N)
Germany, smoking and nicotine dependence, prevalence in primary care 1586
Global Appraisal of Individual Needs (GAIN) and Timeline Followback (TLFB; Form 90) among adolescents in substance abuse treatment 120(S2)
Global Report on Alcohol Policy (WHO) 1363(N&N)
globalization of drug injecting 799(E)

hair testing and self-report of cocaine use by heroin users 590
harm minimization in school drug education: School Health and Alcohol Harm Reduction Project (SHAHRP) 278, 292(C)
Health Internetwork Access to Research Initiative (HINARI), on-line 1363(N&N)
health-care utilization
determinants of sustained injection cessation 727
drug user needs–service match 962
and moderate alcohol use 612
see also hospital admissions; primary care
heart disease
and alcohol consumption 109, 276(E), 313
and smoking, advertising campaign 657(N&N)
helper(s)
helping helps, 12-step groups 1015
syndrome, addiction research and 154
hepatitis A and B, combined vaccine 1560
hepatitis C
brief behavioural intervention 1157
chronic, treatment in patients with drug dependence 1167
intranasal cocaine use does not appear to be a risk factor 973
risk management among injectors in London 621
heroin
dependence, research and policy responses, Australia 560, 1063(Ls)
dependence, substitution therapy service provision into older age 649(L)
discount rates for delayed rewards 461
hair testing and self-report of cocaine use 590
Hooked on Heroin: Drugs and Drifters in a Globalized World 929(BR)
New York State 393(E), 431
overdose, Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD) 450
overdose death, New York City 846
prescribed, or methadone: patients' opinions and experiences 442
Prescribing Heroin: What is the Evidence? 520(BR)
reduced dopamine D4 receptor mRNA expression in lymphocytes of long-term abstinent addicts 251
risk-sensitive foraging theory elucidates risky choices made by addicts 855
shortage, Australia 340, 875, 1063(Ls)
supply and health: new perspectives 275(E)
treatment *see* maintenance treatment; *specific treatments*
see also injecting drug use; opiate users; syringe/needle exchange
highly active antiretroviral therapy, uptake and adherence among HIV-infected people 361, 1064(L)
HIV
-infected people with alcohol and other substance abuse problems 361, 1064(L)
mortality risk among new onset injecting drug users 946
prevalence of injecting drug use in a Russian city 1430
preventive measures among injectors, Belarus 1565
sterile syringe access conditions and variations in risk 1136
sterile syringe access conditions and variations in risk in three US cities 1136
see also AIDS
homicide and alcohol in Russia 937(E), 1034, 1356(L)
homosexuality and drug use, USA 946, 989
hospital admissions
alcohol and drug abuse, Sweden 1298
alcohol misuse, Ireland 1279
household factors, socio-demographic predictors of smoking cessation 770

© 2004 Society for the Study of Addiction

hypnotic sedative drugs, postmarketing study of relative abuse liability of 165

immigrants, alcohol-related disorders in first- and second-generation, Sweden 229
independence, value of in addiction research 157
inhibitory disregulation
  alcohol impairment behaviour in men and women 1237
  neuroimaging and neuropsychological evidence of 1491, 1503(C)
injecting drug use
  changing profiles of users with AIDS, Hispanic population 1147
  drug consumption rooms, EMCDDA report 792(N&N)
  drug driving, Australia 175
  globalization of 799(E)
  and hepatitis 621, 973, 1157, 1167, 1560
  and HIV 946, 1136, 1430, 1565
  intensity as determinant of sustained injection cessation among chronic users 727
  mortality risk among new onset users 946
  non-fatal cocaine over-dose, Australia 1315
  patients never cease to amaze 649(L), 1065(L)
  prevalence in a Russian city 1430
  treatment *see* maintenance treatment; *specific treatments*
  see also heroin; opiate users; syringe/needle exchange
integrated treatments 266(BR), 654(BR), 789(BR)
International Centre for Alcohol Policies (ICAP) 658(IC)
International Harm Reduction Association (IHRA), new director 1484(N&N)
International Narcotics Control Board (INCB), new officers appointed 1071(N&N)
interviews
  Michael A.H. Russell 9
  Charles R. Schuster 667
  Tomoji Yanagita 805
intranasal cocaine use does not appear to be an independent risk factor for HCV infection 973
intravenous drug use *see* injecting drug use
Introductory Guide to Tobacco Control Legislation (WHO) 1485(N&N)
Israel Society for the Prevention of Alcoholism (ISPA), operations closed 1226(N&N)

Japanese Society of Alcohol-Related Problems 419
Jellinek Memorial Award 1071(N&N)

Kabul report, drug research in developing countries 802(E)
ketamine, cognitive and subjective effects in recreational users 1450
Kettil Bruun Society for Social and Epidemiological Research on Alcohol 161
khat users, Yemeni, (SCL-90) 61

LAAM
  serious adverse events, NEPOD study 450
  versus methadone maintenance 509(Ls)
life-course approach to heavy drinking research 1489(E)
lymphocytes, reduced dopamine D4 receptor mRNA expression in abstinent alcohol and heroin addicts 251

maintenance treatment
  Maintenance Treatment of Heroin Addiction: Evidence at the Crossroads 1360(BR)
  opiate agonist, to peer educators 1355(L)
  substitution therapy service provision into older age 649(L)
  see also specific treatments
marijuana *see* cannabis/marijuana
Marijuana Check-up 1323
Marijuana and Madness 1480(BR)
measuring treatment outcomes, adolescent alcohol and drug use 23(S2), 38(S2)
memory, effects of ketamine 1450
mental health *see* comorbidity; dual diagnosis; psychosis/schizophrenia and cannabis
methadone
  -associated and buprenorphine-associated deaths 978
  and excessive sweating 259(L)
  overdose death, New York City 846
  serious adverse events, NEPOD study 450
  standard maintenance versus enriched 180-day methadone detoxification: cost-effectiveness 718
  versus LAAM 509(Ls)
  versus prescribed heroin: patients' opinions and experiences 442
  versus slow-release oral morphine: crossover comparison of patient outcomes and acceptability 940
Methadone Matters: Evolving Community Methadone Treatment of Opiate Addiction 519(BR)
methamphetamine *see* amphetamine
methodological issues
  for enhancing treatment research 47(S2)
  quantity of articles in addiction journals 145(E)
middle-age
  drinking patterns and mortality in men and women 323
  and younger adults 1286
Moo Joose case study, alcohol industry/addiction agency collaboration 1370, 1375(C), 1380
mortality
  alcohol consumption
    Belarus 1364(BR)
    Canada 1274
    effects of brief interventions: meta-analysis 839
    measures 109
    and pancreatitis 1231(E), 1255
    patterns in middle-aged men and women 323
    sensible limits and drinking above lowest-risk level, England and Wales 749
  amphetamine and opiate users, Australia 53
  buprenorphine- and methadone-associated deaths 978
  crack cocaine users, Brazil 1133
  overdose deaths attributed to methadone and heroin, New York City 846
  risk among new onset injecting drug users 946
motivational enhancement/interviewing
  and coping skills training for cocaine abusers 862
  efficacy of single-session 39
  and other brief interventions, adolescent substance abuse 63(S2)

naltrexone and acamprosate in treatment of alcohol dependence 811
National Drug Research Institute (NDRI), Australia 142(N&N)
National Institute on Alcohol Abuse and Alcoholism (NIAAA), US, online bulletin 270(N&N)
National Institute on Drug Abuse (NIDA), US
  Monitoring the Future report 934(N&N)
  professional development opportunities from India 142(N&N)
natural history of alcohol use disorders 5(S2)

© 2004 Society for the Study of Addiction

needle exchange *see* syringe/needle exchange
negative and positive dimensions of psychosis, early adolescent cannabis exposure and 1333, 1351(Ls)
negative reinforcement models, nicotine dependence 5(S1), 79(S1)
Neurobiology of Alcohol and Nicotine Addiction 1482(BR)
neuroimaging and neuropsychological evidence of inhibitory disregulation 1491, 1503(C)
Neuroscience of Psychoactive Substance Use and Dependence 1361(BR)
New Mexico, 1998 drive-up liquor window closure studies 598, 607
New Treatments for Addiction: Behavioural, Ethical, Legal and Social Questions 1481(BR)
New Zealand, gender convergence in alcohol consumption and related problems 738
nicotine dependence
  effects on diurnal variations of subjective activation and mood 1599
  increasing the involvement of primary health care 299
  marijuana as 'gateway' drug 5(E), 77
  models and measurement 1(S1)
    cognitive and social learning 51(S1), 80(S1)
    negative reinforcement 5(S1), 79(S1)
    positive reinforcement 30(S1), 80(S1)
    value of 78(S1)
  Michael A.H. Russell (interview) 9
  see also smoking; smoking cessation; tobacco industry; tobacco research
nicotine lozenge 83
nicotine patch, effect of pre-treatment on withdrawal symptoms and abstinence rates 634
'non-intervention ethos', needle exchange users 270(N&N)

older people
  alcohol consumption and drinking problems, ten-year patterns 829
  five-year alcohol and drug treatment outcomes of, middle-aged and younger adults 1286
  heroin dependence, substitution therapy service provision 649(L)
  reduction of quantity smoked predicts future cessation 93
online information
  Addiction 7(E)
  Alcohol Information Scotland 792(N&N)
  European Association of Libraries and Information Services on Alcohol and other Drugs (ELISAD) 657(N&N)
  European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 1364(N&N)
  Exchange on Drug Demand Reduction Actions (EDDRA) 1072(N&N)
  Health Internetwork Access to Research Initiative (HINARI) 1363(N&N)
  National Institute on Alcohol Abuse and Alcoholism (NIAAA) 270(N&N)
opiate users
  cohort of, and amphetamine users, Australia 53
  Confessions of an English Opium Eater (de Quincey) 1221(BR)
  depression and hostility as predictors of long-term outcomes 579
  Narcotic Culture: A History of Drugs in China 1067(BR)
  treatment *see* maintenance treatment: *specific treatments*
  see also heroin; injecting drug use; syringe/needle exchange
overdose
  deaths attributed to methadone and heroin, New York City 846
  non-fatal, cocaine users, Australia 1315

parental drug use 552, 955
parental smoking, adolescent initiation, inattentiveness and 1049
'parentification' 1226(IC)
passive smoking, stepping up pressure on 389(N&N)
per capita alcohol consumption 1255, 1274
personality disorder
  antisocial, alcoholic subtype 1508
  and associated comorbidity in alcohol and drug services 1306
personality, Five-Factor Model (FFM), smoking and 472
Pharmacotherapy of Addiction 267(BR)
photo history series, addiction recovery mutual aid groups 532
Politics and Economics of Drug Production on the Pakistan–Afghanistan Border 786(BR)
positive and negative dimensions of psychosis, early adolescent cannabis exposure and 1333, 1351(Ls)
positive reinforcement models, nicotine dependence 30(S1), 80(S1)
pregnancy
  buprenorphine in opioid-dependent women: prospective study 209
  Conceiving Risk, Bearing Responsibility: Fetal Alcohol Syndrome and the Diagnosis of Moral Disorder 1069(BR)
  risky drinking and alcohol use patterns in national sample of women of child-bearing age 1393
primary care 103, 1470, 1586
prize reinforcement contingency management, treatment of cocaine users 349
psychological determinants of low-rate daily smoking 1342
psychological symptoms
  adverse, in Yemeni khat users, by Symptoms Checklist-90 (SCL-90) 61
  childhood externalising and internalizing psychopathology in prediction of early substance abuse 1548
  see also comorbidity; dual diagnosis
psychosis/schizophrenia and cannabis 425, 511(Ls), 1333, 1351(Ls), 1480(BR)
psychosocial approaches for treatment of methamphetamine dependence 708
psychosocial characteristics, drug use by Brazilian students 570
psychosocial outcomes, drinking patterns in mid-adolescence and, in late adolescence and early adulthood 1529

relapse curve shape and long-term abstinence among untreated smokers 29
relapse trajectory cluster groups among adolescents discharged from out-patient treatment 129(S2)
research career issues 149(E), 151, 152, 159
Reward and Dependence—a Psychological and Neurobiological Analysis of Reward Mechanisms and their Role in Dependence 1482(BR)
rewards, discount rates for delayed 461
risk-sensitive foraging theory elucidates risky choices made by heroin addicts 855
Russell, Michael A.H. (interview) 9
Russia
  alcohol
    and homicide 937(E), 1034, 1356(L)
    is monitoring health conditions trustworthy? 386(L)
  injecting drug use, prevalence of 1430
  see also former Soviet Union

© 2004 Society for the Study of Addiction

schizophrenia/psychosis and cannabis 425, 511(Ls), 1333, 1351(Ls), 1480(BR)
school dropout rate reduction, cannabis use prevention and 650(Ls)
school-based intervention/prevention 106(S2), 133(BR), 278
Schuster, Charles R. (interview) 667
scientific societies
  Japanese Society of Alcohol-Related Problems 419
  Kettil Bruun Society for Social and Epidemiological Research on Alcohol 161
  Society for the Study of Addiction (SSA), UK 677
scratchcard gambling 117
Seixas Award/Research Society on Alcoholism 1226(N&N)
self-report
  audio-computerized self-interviewing versus face-to-face interviewing at drug abuse treatment programs 885
  and hair testing of cocaine use by heroin users 590
  under-reporting of alcohol consumption in household surveys 1024
serious adverse events in Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD) 450
single-session motivational interviewing, efficacy of, in reducing drug consumption and risk among young people 39
slow-release oral morphine versus methadone 940
smokeless tobacco (SLT) 260(L), 262(L)
smoking
  determinants in eight countries of former Soviet Union 1577
  and Five-Factor Model (FFM) of personality 472
  initiation in adolescence, inattentiveness and parental smoking 1049
  intentions, role in predicting future smoking among youth 914
  and nicotine dependence, prevalence in primary care, Germany 1586
  perceived peer, prevalence and its association with smoking behaviours and intentions 1195
  psychological determinants of low-rate daily 1342
  risks graphically portrayed, BHF advertising campaign 657(N&N)
  see also cannabis/marijuana; nicotine dependence; smoking cessation; tobacco industry; tobacco research
smoking cessation
  abstinence rates and outcome predictors, Brazil 778
  bupropion 237, 1206, 1462, 1470
  direct telemarketing of interventions 907
  experimenter-designed quit dates: adherence improves outcomes for women but not for men 378
  heterogeneity in 12-month outcome among female and male smokers 237
  knowledge and perceived effectiveness of assistance as predictors of behaviour 1042
  nicotine replacement 83, 634, 1470
  personally tailored computer-generated advice letters 369
  reduction of quantity smoked predicts future cessation among older smokers 93
  shape of relapse curve and long-term abstinence among untreated smokers 29
  socio-demographic predictors: how important are household factors? 770
  ten-point plan 657(N&N)
  see also nicotine dependence
social environment *see* environment
social learning models of drug dependence 51(S1), 80(S1)
social and solitary risky single occasion drinkers, emotional wellbeing and violence in adolescence 331
Society for the Study of Addiction (SSA), UK 677
South Africa, doctors call for alcohol injury fund 141(N&N)
spirituality, addiction and 539
standards for reporting non-randomized evaluations of interventions 1075(E)
substance abuse treatment needs, US 938(E), 999, 1219(L)
Substance Use and Abuse: Cultural and Historical Perspectives 655(BR)
substitution therapy *see* maintenance treatment; *specific treatments*
Symptoms Checklist-90 (SCL-90), exploration of adverse psychological symptoms in Yemeni khat users by 61
syringe/needle exchange
  access conditions and variations in HIV risk 1136
  assessing programs 1081(E)
  'non-intervention ethos' 270(N&N)
telephone counselling, for smoking cessation 907
time-frames typology, Swiss alcohol and drug clinics 1418
Timeline Followback (TLFB; Form 90) and Global Appraisal of Individual Needs (GAIN) among adolescents in substance abuse treatment 120(S2)
tobacco *see* nicotine dependence; smoking; smoking cessation
tobacco industry
  case for controlling 529(E)
  Introductory Guide to Tobacco Control Legislation (WHO) 1485(N&N)
  revealing insights from (BAT) Guildford Depository 394(E)
  university funding, UK 1226(N&N)
tobacco research
  Tobacco Etiology Research Network (TERN) 1(S1)
  UK (TRUK) 524(N&N)
TREND statement, standards for reporting non-randomized evaluations of interventions 1075(E)
Turkey, ecstasy use among students 67
12-step groups, help the helper 1015
twin studies 1403, 1548

United Kingdom (UK)
  alcohol policies 518(BR), 1083, 1090(C), 1477(L), 1487(E)
  drinking limits/levels and mortality 749
  Gambling and Problem Gambling in Great Britain 516(BR)
  GP prescribing of nicotine replacement and bupropion 1470
  hepatitis C and its risk management among drug injectors, London 621
  Scotland 269(N&N), 792(N&N)
  smoking and BHF advertising campaign 657(N&N)
  Society for the Study of Addiction (SSA), UK 677
  tobacco industry funding of universities 1226(N&N)
  tobacco research (TRUK) 524(N&N)
United States (US)
  American Drinking Practices 1612(BR)
  Drunkards Refuge: The Lessons of the New York State Inebriate Asylum 1360(BR)
  homosexuality and drug use 946, 989
  National Alcohol Surveys 1111
  National Institute on Alcohol Abuse and Alcoholism (NIAAA), online bulletin 270(N&N)

© 2004 Society for the Study of Addiction

National Institute on Drug Abuse (NIDA) 142(N&N), 934(N&N)
New York, drug use issues 393(E), 431, 846
sterile syringe access conditions and variations in HIV risk 1136
substance abuse treatment needs 938(E), 999, 1219(L)
urbanization and hospital admission rates for alcohol and drug abuse, Sweden 1298
violence
and alcohol 331, 937(E), 1034, 1356(L)
Bouncers: Violence and Governance in the Night Time Economy 265(BR)
web-based screening and brief intervention for hazardous drinking 1410
websites *see* online information
whisky distillery, Scotland 269(N&N)
Wine: A Scientific Exploration 1362(BR)
women *see* gender; pregnancy
World Health Organization (WHO) 1363(N&N), 1485(N&N)
Yanagita, Tomoji (interview) 805
Yemeni khat users, (SCL-90) 61
Young People and Substance Misuse 1359(BR)

© 2004 Society for the Study of Addiction